Pre-made Lodelcizumab biosimilar ( Whole mAb, anti-PCSK9 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-318
Anti-PCSK9 therapeutic antibody (Pre-made Lodelcizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ligelizumab (QGE031) is a humanized monoclonal antibody (mAb) designed for the treatment of severe asthma and chronic spontaneous urticaria. his drug was developed by Novartis Pharma AG. As of 2018, ligelizumab is undergoing Phase III trials. It binds with high affinity to the C��3 domain of IgE.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PCSK9 therapeutic antibody (Pre-made Lodelcizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|